Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVJF) Dividends Paid - Common (2016 - 2018)

Historic Dividends Paid - Common for Teva Pharmaceutical Industries (TEVJF) over the last 10 years, with Q1 2018 value amounting to $12.0 million.

  • Teva Pharmaceutical Industries' Dividends Paid - Common fell 9653.18% to $12.0 million in Q1 2018 from the same period last year, while for Dec 2018 it was $12.0 million, marking a year-over-year decrease of 9866.81%. This contributed to the annual value of $52.0 million for FY2019, which is 33333.33% up from last year.
  • According to the latest figures from Q1 2018, Teva Pharmaceutical Industries' Dividends Paid - Common is $12.0 million, which was down 9653.18% from $87.0 million recorded in Q4 2017.
  • In the past 5 years, Teva Pharmaceutical Industries' Dividends Paid - Common registered a high of $2.0 billion during Q4 2014, and its lowest value of -$299.0 million during Q2 2014.
  • Over the past 5 years, Teva Pharmaceutical Industries' median Dividends Paid - Common value was $49.5 million (recorded in 2017), while the average stood at $323.4 million.
  • Per our database at Business Quant, Teva Pharmaceutical Industries' Dividends Paid - Common soared by 67666.67% in 2017 and then crashed by 9653.18% in 2018.
  • Teva Pharmaceutical Industries' Dividends Paid - Common (Quarter) stood at $2.0 billion in 2014, then crashed by 43.38% to $1.2 billion in 2015, then grew by 29.35% to $1.5 billion in 2016, then plummeted by 94.18% to $87.0 million in 2017, then plummeted by 86.21% to $12.0 million in 2018.
  • Its Dividends Paid - Common stands at $12.0 million for Q1 2018, versus $87.0 million for Q4 2017 and $123.0 million for Q3 2017.